Press Releases Latest Mar 14, 2023 Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model Press Releases Year None20232022202120202019201820172016201520142013 Feb 25, 2021 Theratechnologies to Present at the H.C. Wainwright Global Life Sciences Conference Feb 25, 2021 Theratechnologies Announces Fourth-Quarter And Fiscal-Year 2020 Financial Results Feb 11, 2021 Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020 Feb 04, 2021 Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers Jan 19, 2021 Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option Jan 15, 2021 Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version) Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version) Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering Of Units Jan 07, 2021 Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities First page « Previous page ‹ … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page › Last page » Displaying 71 - 80 of 305
Mar 14, 2023 Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
Feb 04, 2021 Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers
Jan 19, 2021 Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Jan 15, 2021 Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference
Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version)
Jan 11, 2021 Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version)
Jan 07, 2021 Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities
